Immunotherapy of colorectal cancer - Overview and perspectives;Immuntherapie des kolorektalkarzinoms - Aktueller stand und perspektiven

Zeitschrift fur Gastroenterologie

Volumn 44, Issue 8, 2006, Pages 673-681

  Schimanski, C C ^a   Horner V ^a   Kanzler, S ^a   Galle, P R ^a   Möhler, Markus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Clinical trials; Colorectal cancer; Immunotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR; FLUOROURACIL; IMMUNOMODULATING AGENT; LEVAMISOLE; VASCULOTROPIN;

ALLELE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TOLERANCE; GENETIC ANALYSIS; HLA TYPING; HUMAN; IMMUNE RESPONSE; REVIEW; VACCINATION;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 33748646756     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926905     Document Type: Review

References (80)

1. Agelaki S, Georgoulias V. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs 2005; 10 (4): 855-874
2. Albanopoulos K, Armakolas A, Konstadoulakis MM et al. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol 2000; 95 (4): 1056-1061
3. Amin S, Robins RA, Maxwell-Armstrong CA et al. Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res 2000; 60 (12): 3132-3136
4. Arina A, Tirapu I, Alfaro C et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells exploiting cross-priming. Exp Hematol 2002; 30 (12): 1355-1364
5. Basak S, Eck S, Gutzmer R et al. Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Ann N Y Acad Sci 2000; 910: 237-252; discussion 252-233
6. Behrens RJ, Achtar M, Herrin V. Phase I/II mutant p53 vaccination in advanced malignancies. Proc Natl Acad Sci U S A 2003; 22: 186
7. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002; 23 (4): 201-208
8. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99 (3): 754-758
9. Conry RM, Allen KO, Lee S et al. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res 2000; 6 (1): 34-41
10. Conry RM, Curiel DT, Strong TV et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002; 8 (9): 2782-2787
11. Conry RM, Khazaeli MB, Saleh MN et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5 (9): 2330-2337
12. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 (4): 337-345
13. Dalerba P, Maccalli C, Casati C et al. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46 (1): 33-57
14. Fagerberg J, Steinitz M, Wigzell H et al. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci U S A 1995; 92 (11): 4773-4777
15. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333 (2): 328-335
16. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23 (18): 4117-4126
17. Folprecht G, Lutz MP, Schoffski P et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17 (3): 450-456
18. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98 (15): 8809-8814
19. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999; 17 (9): 2889-2885
20. Ganti AK, Potti A. Epidermal growth factor inhibition in solid tumours. Expert Opin Biol Ther 2005; 5 (9): 1165-1174
21. Ghanekar SA, Nomura LE, Suni MA et al. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol 2001; 8 (3): 628-631
22. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4 (5): 401-411
23. Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92 (3): 441-450
24. Goydos JS, Elder E, Whiteside TL et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63 (1): 298-304
25. Habal N, Gupta RK, Bilchik AJ et al. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001; 8 (5): 389-401
26. Hanahan D, Lanzavecchia A, Mihich E. Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors. Cancer Research 2003; 63 (11): 3005-3008
27. Hanna MGJ, Hoover HCJ, Vermorken JB et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001; 21 (19): 2576-2582
28. 2S Harris JE, Ryan L, Hoover Jr HC et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18 (1): 148-157
29. Himmler G, Schuster M, E nnn J. Murine monoclonal antibody 17-1A used as a vaccine antigen: Direct induction of anti-EpCAM antibodies by vaccination of cancer patients. Proc Am Soc Clin Oncol 2003; 22: 183
30. Hoover Jr HC, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11 (3): 390-399
31. Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000; 49 (9): 504-514
32. Ibrahim RA, Herrin V, Gause B. Mutant p53 vaccination of patients with advanced cancers generates specific immunological responses. Proc Natl Acad Sci U S A 2004; 22: 2521
33. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71 (6): 907-920
34. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother 2001; 24 (2): 172-183
35. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003; 2 (2): 305-315
36. Laurie Ja, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. Journal of Clinical Oncology 1990; 7: 1447-1456
37. Liang W, Wang H, Sun TM et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 2003; 9 (3): 495-498
38. Liebrich W, Schlag P, Manasterski M et al. In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 1991; 27 (6): 703-710
39. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004; 10 (8): 2645-2651
40. Loibner H, Eller N, Groiss F. A randomized placebo-controlled phase II study with cancer vaccine IGN101 in patients with epithelial solid organ tumors. Proc Natl Acad Sci U S A 2004; 22: 14-16
41. MacLean GD, Reddish MA, Koganty RR et al. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19 (1): 59-68
42. Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005; 23 (4): 720-731
43. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18 (23): 3964-3973
44. Matsuda K, Tsunoda T, Tanaka H et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004; 53 (7): 609-616
45. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001; 84 (11): 1443-1446
46. Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003; 9 (9): 3235-3245
47. Mellstedt H, Fagerberg J, Frodin JE et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 1999; 6 (3): 169-175
48. Menon AG, Kuppen PJ, van der Burg SH et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 2003; 10 (7): 509-517
49. Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001; 7 (12): 3950-3962
50. Moehler M, Teufel A, Galle PR. New chemotherapeutic strategies in colorectal cancer. Recent Results Cancer Res 2005; 165: 250-259
51. Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21 (3): 341-349
52. Mosolits S, Markovic K, Frodin JE et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 2004; 10 (16): 5391-5402
53. Moulton HM, Yoshihara PH, Mason DH et al. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002; 8 (7): 2044-2051
54. Mukohara T, Engelman JA, Hanna NH et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97 (16): 1185-1194
55. Neidhart J, Allen KO, Barlow DL et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 2004; 22 (5/6): 773-780
56. Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996; 2 (1): 21-28
57. Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94 (2): 153-156
58. Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360 (9334): 671-677
59. Riemer AB, Kurz H, Klinger M et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005; 97 (22): 1663-1670
60. Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. Journal of Clinical Oncology 1998; 16 (5): 1788-1794
61. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673-1684
62. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7 (8): 2277-2284
63. Saleh MN, LoBuglio AF et al. A phase II trial of murine monoclonal antibody l7-1A and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother 1990; 32 (3): 185-190
64. Samonigg H, Wilders-Truschnig M, Kuss I et al. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J Immunother 1999; 22 (6): 481-488
65. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23 (22): 5027-5033
66. Slack R, Chang P, Arlen P. Association between CEA-spedfic T-cell responses following treatment with vaccina-CEA and ALVAC-CEA and survival in patinets with CEA-bearing cancers. Proc Natl Acad Sci U S A 2001; 20: 272A
67. Staib L, Birebent B, Somasundaram R et al. Immunogenicity of recombinant GA733-2E antigen (C017-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001; 92 (1): 79-87
68. Tartour E, Benchetrit F, Haicheur N et al. Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols. Vaccine 2002; 20 (4): 32-39
69. Thieme H, Aiello LP, Takagi H et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995; 44 (1): 98-103
70. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87 (13): 982-990
71. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2 (1): 19
72. Ueda Y, Itoh T, Nukaya I et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004; 24 (4): 909-917
73. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004; 10 (10): 3273-3281
74. Ullenhag GJ, Frodin JE, Mosolits S et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 2003; 9 (7): 2447-2456
75. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353 (9150): 345-350
76. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7 (5): 1181-1191
77. von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000; 6 (6): 2219-2228
78. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 2001; 28 (1 Suppl 1): 9-13
79. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80 (1): 30-36
80. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005; 16: 847-862